NCT05018299

Evaluate the Efficacy and Safety of FB704A in Adult With Severe Asthma

A Randomized, Placebo Controlled, Double Blind Phase IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Multiple Intravenous Doses of FB704A in Adults With Severe Asthma

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Oneness Biotech Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized, placebo controlled and double blind study to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of FB704A in adult patients with severe asthma. The study comprised a 4-week screening period, a 8-week treatment period and a 12-week follow-up period.

Detailed description

Approximately 20 subjects who meet the criteria for study entry are planned to be enrolled to the study. Eligible subjects will be randomized to receive placebo or FB704A in a 1:1 ratio, with an estimated 10 subjects per treatment arm. Eligibility will be checked in patients with severe asthma during the 4-week screening period. Potential candidates should provide signed informed consent forms before starting the screening activities. The subjects will receive four dose of 4 mg/kg FB704A or placebo. The study drug will be administered as a 1-hour IV infusion. Patients may administer Short-acting beta agonists (SABAs), such as albuterol as rescue medications as needed throughout the study. Subjects will have site visits after receiving study drug for efficacy, safety, PK, and biomarker evaluation (see Study Flow Chart). Subjects who prematurely withdraw from the study will have an end of study (EOS) visit within 7 days. Relative change in pre-bronchodilator FEV 1 , post-bronchodilator FEV 1, exhaled NO and asthma symptom s will be evaluated during the study.

Conditions

• Severe Asthma

Interventions

Type	Name	Description
BIOLOGICAL	FB704A placebo	Placebo
BIOLOGICAL	FB704A	Anti-IL-6 antibody

Timeline

• Start date: 2021-09-30
• Primary completion: 2026-02-13
• Completion: 2026-05-08
• First posted: 2021-08-24
• Last updated: 2025-12-09

Locations

9 sites across 1 country: Taiwan

Regulatory

• FDA-regulated drug study